Advertisement

MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma

  • Gamal Shiha
    Correspondence
    Corresponding author. Address: Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt. CEO, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. Tel.: +2 01223280501.
    Affiliations
    European Liver Patients' Association (ELPA), Brussels, Belgium

    World Hepatitis Alliance, London, UK

    African Liver Patient Association (ALPA), Cairo, Egypt

    The Association of Liver Patients Care (ALPC), Egypt

    Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt

    Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt
    Search for articles by this author
  • Marko Korenjak
    Affiliations
    European Liver Patients' Association (ELPA), Brussels, Belgium

    Association SLOVENIA HEP, Maribor, Slovenia
    Search for articles by this author
  • Teresa Casanovas
    Affiliations
    European Liver Patients' Association (ELPA), Brussels, Belgium

    Asociación Catalana de Pacientes Hepáticos (ASSCAT), Barcelona, Spain
    Search for articles by this author
  • Vicki Mooney
    Affiliations
    The European Coalition for People Living with Obesity (EASO ECPO), Dublin, Ireland
    Search for articles by this author
  • Sólveig Sigurðardóttir
    Affiliations
    The European Coalition for People Living with Obesity (EASO ECPO), Dublin, Ireland
    Search for articles by this author
  • Yiannoula Koulla
    Affiliations
    European Liver Patients' Association (ELPA), Brussels, Belgium

    Cyprus Liver Patients Association, Cyprus
    Search for articles by this author
  • Reham Soliman
    Affiliations
    European Liver Patients' Association (ELPA), Brussels, Belgium

    The Association of Liver Patients Care (ALPC), Egypt

    Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt

    Tropical Medicine Department, Faculty of Medicine, Port Said University, Egypt
    Search for articles by this author
Published:August 30, 2022DOI:https://doi.org/10.1016/j.jhep.2022.08.027
      Metabolic (dysfunction) associated fatty liver disease (MAFLD) is a highly prevalent and complex condition
      • Chan K.E.
      • Koh T.J.L.
      • Tang A.S.P.
      • Quek J.
      • Yong J.N.
      • Tay P.
      • et al.
      Global prevalence and clinical characteristics of metabolic associated fatty liver disease. A meta-analysis and systematic review of 10,739,607 individuals.
      and can lead to serious complications such as liver failure and liver cancer. MAFLD also increases the risk of non-liver complications such as cardiovascular disease, diabetes and chronic kidney disease.
      • Eslam M.
      • Sarin S.K.
      • Wong V.W.-S.
      • Fan J.-G.
      • Kawaguchi T.
      • Ahn S.H.
      • et al.
      The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chan K.E.
        • Koh T.J.L.
        • Tang A.S.P.
        • Quek J.
        • Yong J.N.
        • Tay P.
        • et al.
        Global prevalence and clinical characteristics of metabolic associated fatty liver disease. A meta-analysis and systematic review of 10,739,607 individuals.
        J Clin Endocrinol Metab. 2022; 107: 2691-2700https://doi.org/10.1210/clinem/dgac321
        • Eslam M.
        • Sarin S.K.
        • Wong V.W.-S.
        • Fan J.-G.
        • Kawaguchi T.
        • Ahn S.H.
        • et al.
        The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.
        Hepatol Int. 2020; 14: 889-919
        • Shiha G.
        • Korenjak M.
        • Eskridge W.
        • Casanovas T.
        • Velez-Moller P.
        • Högström S.
        • et al.
        Redefining fatty liver disease: an international patient perspective.
        Lancet Gastroenterol Hepatol. 2021; 6: 73-79
        • Alqahtani S.A.
        • Paik J.M.
        • Biswas R.
        • Arshad T.
        • Henry L.
        • Younossi Z.M.
        Poor awareness of liver disease among adults with NAFLD in the United States.
        Hepatol Commun. 2021; 5: 1833-1847
        • Eslam M.
        • Ahmed A.
        • Després J.-P.
        • Jha V.
        • Halford J.C.
        • Chieh J.T.W.
        • et al.
        Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.
        Lancet Gastroenterol Hepatol. 2021; 6: 743-753
        • Alharthi J.
        • Gastaldelli A.
        • Cua I.H.
        • Ghazinian H.
        • Eslam M.
        Metabolic dysfunction-associated fatty liver disease: a year in review.
        Curr Opin Gastroenterol. 2022; 38: 251-260
        • Goffman E.
        Stigma: notes on the management of spoiled identity.
        Simon and schuster, 2009
        • Eslam M.
        • Alkhouri N.
        • Vajro P.
        • Baumann U.
        • Weiss R.
        • Socha P.
        • et al.
        Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
        Lancet Gastroenterol Hepatol. 2021; 6: 864-873
        • Shiha G.
        • Alswat K.
        • Al Khatry M.
        • Sharara A.I.
        • Örmeci N.
        • Waked I.
        • et al.
        Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
        Lancet Gastroenterol Hepatol. 2021; 6: 57-64
        • Thomas S.L.
        • Hyde J.
        • Karunaratne A.
        • Herbert D.
        • Komesaroff P.A.
        Being ‘fat’in today’s world: a qualitative study of the lived experiences of people with obesity in Australia.
        Health Expect. 2008; 11: 321-330
        • Vartanian L.
        “Obese people” vs “Fat people”: impact of group label on weight bias. Eating and Weight Disorders-Studies on Anorexia.
        Bulimia Obes. 2010; 15: e195-e198
        • Karlsen T.H.
        • Sheron N.
        • Zelber-Sagi S.
        • Carrieri P.
        • Dusheiko G.
        • Bugianesi E.
        • et al.
        The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
        The Lancet. 2022; 399: 61-116